Tokyo, Feb. 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060542) titled 'Research trends on the use of blonanserin for delirium: a scoping review' on Feb. 1.
Study Type:
Others,meta-analysis etc
Primary Sponsor:
Institute - Hiroshima Red cross Hospital and Atomic-bomb survivors Hospital
Condition:
Condition - delirium
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To systematically map existing literature on the use of blonanserin for delirium
Basic objectives2 - Safety,Efficacy
Eligibility:
Age-lower limit - 18
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - 1) Research on the use of blonanserin for delirium in medically ill.
Key exclusion criteria - 1) Duplicate publications
2) Research for subjects with other psychiatric diagnosis (e.g., Schizophrenia, Bipolar disorder)
3) Articles written in languages other than English or Japanese
Recruitment Status:
Recruitment status - No longer recruiting
Date of protocol fixation - 2025 Year 06 Month 29 Day
Date of IRB - 2025 Year 06 Month 29 Day
Anticipated trial start date - 2025 Year 06 Month 30 Day
Last follow-up date - 2025 Year 07 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000066680
Disclaimer: Curated by HT Syndication.
